16th Sep 2024 Plain language summary of the ASCENT Study: Sacituzumab Govitecan for metastatic triple-negative breast cancer
1st Sep 2021 A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer
